JPH04500009A - 遺伝子機能の多価リプレッサー - Google Patents
遺伝子機能の多価リプレッサーInfo
- Publication number
- JPH04500009A JPH04500009A JP2507933A JP50793390A JPH04500009A JP H04500009 A JPH04500009 A JP H04500009A JP 2507933 A JP2507933 A JP 2507933A JP 50793390 A JP50793390 A JP 50793390A JP H04500009 A JPH04500009 A JP H04500009A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- rex
- gene
- rev
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 309
- 101710150336 Protein Rex Proteins 0.000 claims abstract description 266
- 230000014509 gene expression Effects 0.000 claims abstract description 98
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims abstract description 57
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 48
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 44
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims abstract description 41
- 101710150344 Protein Rev Proteins 0.000 claims abstract description 35
- 230000003612 virological effect Effects 0.000 claims abstract description 23
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 241000894007 species Species 0.000 claims abstract description 15
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 164
- 210000004027 cell Anatomy 0.000 claims description 109
- 230000035772 mutation Effects 0.000 claims description 87
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 83
- 108020004999 messenger RNA Proteins 0.000 claims description 73
- 230000000694 effects Effects 0.000 claims description 69
- 241000700605 Viruses Species 0.000 claims description 65
- 108020004414 DNA Proteins 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 56
- 108700026241 pX Genes Proteins 0.000 claims description 54
- 239000013598 vector Substances 0.000 claims description 47
- 101150103375 rex gene Proteins 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 30
- 230000010076 replication Effects 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 230000004913 activation Effects 0.000 claims description 26
- 230000004807 localization Effects 0.000 claims description 24
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 claims description 20
- 230000001629 suppression Effects 0.000 claims description 20
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 19
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 19
- 108700004030 rev Genes Proteins 0.000 claims description 17
- 230000004853 protein function Effects 0.000 claims description 14
- 101150098213 rev gene Proteins 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 108091027981 Response element Proteins 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 239000012636 effector Substances 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000003278 mimic effect Effects 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000713325 Visna/maedi virus Species 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 238000012217 deletion Methods 0.000 abstract description 37
- 230000037430 deletion Effects 0.000 abstract description 37
- 230000003834 intracellular effect Effects 0.000 abstract description 5
- 230000001413 cellular effect Effects 0.000 abstract description 4
- 108700005077 Viral Genes Proteins 0.000 abstract description 3
- 239000003443 antiviral agent Substances 0.000 abstract description 3
- 238000010195 expression analysis Methods 0.000 abstract description 2
- 230000001052 transient effect Effects 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000000754 repressing effect Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 description 118
- 235000001014 amino acid Nutrition 0.000 description 108
- 235000018102 proteins Nutrition 0.000 description 103
- 229940024606 amino acid Drugs 0.000 description 41
- 150000001413 amino acids Chemical class 0.000 description 38
- 101710149951 Protein Tat Proteins 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 32
- 238000001114 immunoprecipitation Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 23
- 238000009739 binding Methods 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 108091026890 Coding region Proteins 0.000 description 19
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- 230000027455 binding Effects 0.000 description 19
- 101900102211 Human T-cell leukemia virus 1 Protein Rex Proteins 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 16
- 210000004940 nucleus Anatomy 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
- 230000001086 cytosolic effect Effects 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 102000006392 myotrophin Human genes 0.000 description 12
- 108010058605 myotrophin Proteins 0.000 description 12
- 230000026731 phosphorylation Effects 0.000 description 12
- 238000006366 phosphorylation reaction Methods 0.000 description 12
- 208000030507 AIDS Diseases 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108010078428 env Gene Products Proteins 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 241001430294 unidentified retrovirus Species 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 108091006104 gene-regulatory proteins Proteins 0.000 description 10
- 102000034356 gene-regulatory proteins Human genes 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 102100034353 Integrase Human genes 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 108700004025 env Genes Proteins 0.000 description 9
- 101150030339 env gene Proteins 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 108010021466 Mutant Proteins Proteins 0.000 description 8
- 102000008300 Mutant Proteins Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 230000002788 anti-peptide Effects 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 108010038751 tax Gene Products Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012761 co-transfection Methods 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000030648 nucleus localization Effects 0.000 description 6
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 101710177291 Gag polyprotein Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000000869 mutational effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 230000004960 subcellular localization Effects 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001524679 Escherichia virus M13 Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 108091032917 Transfer-messenger RNA Proteins 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 108700004027 tat Genes Proteins 0.000 description 3
- 101150098170 tat gene Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 3
- 230000006648 viral gene expression Effects 0.000 description 3
- ZBFPLELNWIASCT-UHFFFAOYSA-N 4-phenyl-4,5-dihydro-1,3-oxazol-2-amine Chemical group C1OC(N)=NC1C1=CC=CC=C1 ZBFPLELNWIASCT-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 235000005340 Asparagus officinalis Nutrition 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241001101077 Crex Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101900141355 Human T-cell leukemia virus 1 Protein Tax-1 Proteins 0.000 description 2
- 101000756400 Human T-cell leukemia virus 2 Protein Rex Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000013000 chemical inhibitor Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000035903 transrepression Effects 0.000 description 2
- NBIIXXVUZAFLBC-HOSYLAQJSA-K trioxido(oxo)-$l^{5}-phosphane Chemical compound [O-][32P]([O-])([O-])=O NBIIXXVUZAFLBC-HOSYLAQJSA-K 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- LWOJOYMIINQEFC-UHFFFAOYSA-N (2-cyanoethylamino)phosphonous acid Chemical compound OP(O)NCCC#N LWOJOYMIINQEFC-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- ALZVPLKYDKJKQU-XVKPBYJWSA-N Ala-Tyr Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ALZVPLKYDKJKQU-XVKPBYJWSA-N 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102100028285 DNA repair protein REV1 Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100411708 Danio rerio rarga gene Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101000935583 Escherichia coli (strain K12) Blue light- and temperature-regulated antirepressor BluF Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241001272178 Glires Species 0.000 description 1
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241001026509 Kata Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- HFKJBCPRWWGPEY-BQBZGAKWSA-N L-arginyl-L-glutamic acid Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HFKJBCPRWWGPEY-BQBZGAKWSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- OIDKVWTWGDWMHY-RYUDHWBXSA-N Pro-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 OIDKVWTWGDWMHY-RYUDHWBXSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 101100042631 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIN3 gene Proteins 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000014155 detection of activity Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000009344 polyculture Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010066381 preproinsulin Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (22)
- (1)1種以上のウイルス種の機能的に等価な遺伝子の表現型発現をトランス優 性に抑制し、したがって1種以上のウイルス種の複製を阻止するタンパク質を暗 号化している遺伝子、またはその機能的な断片または誘導体。
- (2)1種以上のウイルス種の機能的に等価な遺伝子の表現型発現をトランス優 性に抑制し、したがって1種以上のウイルス種の複製を阻止するタンパク質、ま たはその機能的な断片または誘導体。
- (3)それによって抑制される遺伝子が、HTLV−Irex、HTLV−Hr ex、HIV−1rev、HIV−Hrev、SIVrev、EIAVrev、 ビスナウイルスrev、およびウシ免疫不全ウイルスrevの2種またはそれ以 上から選ばれたものである請求項1記載の遺伝子、または請求項2記載のタンパ ク質、または 抑制される遺伝子が、HTLV−IrexおよびHIV−1revである請求項 1記載の遺伝子、または請求項2記載のタンパク質、または 抑制される遺伝子が、HIV−1revおよびHIV−2revである請求項1 記載の遺伝子、または請求項2記載のタンパク賃、または、 野生型Rexタンパク質の約22〜101の間、好ましくは約82〜約97の間 、ことに約87〜約94の間のアミノ酸位置に突然変異体を有するHTLV−I Rexタンパク質を暗号化している請求項1記載の遺伝子、またはHTLV−I Rexタンパク質である請求項2記載のタンパク質、または 寿生型Rexタンパク質の約59〜121の間、好ましくは約59、60、64 、65、119、120、または121のアミノ酸位置に突然変異体を有するH TLV−IRexタンパク質を暗号化している請求項1記載の遺伝子、またはH TLV−IRexタンパク質である請求項2記載のタンパク質、または野生型R evタンパク質の約68〜90の間、好ましくは約78〜約86の間、ことに約 78〜約83または84の間のアミノ酸位置に突然変異体を有するHIV−1R evタンパク質を暗号化している請求項1記載の遺伝子、またはHIV−1Re vタンパク質である請求項2記載のタンパク質、または pcRexM2、pcRexM7、およびpcRexM8、M6、M7およびM 13、およびpM10の遺伝子またはタンパク質、またはそれらから誘導された 遺伝子またはタンパク質から選ばれた請求項1記載の遺伝子、または請求項2記 載のタンパク質、または機能的なその断片または誘導体。
- (4)HTLV−Irex遺伝子の表現型発現をトランス優性に抑制するタンパ ク質を暗号化している遺伝子、またはタンパク質、または機能的なその断片また は誘導体。
- (5)それによってHTLV−Irex遺伝子の表現型発現が抑制される請求項 4記載の遺伝子またはタンパク質、または野生型Rexタンパク質の約22〜1 01の間、好ましくは約82〜約97の間、ことに約87〜約94の間のアミノ 酸位置に突然変異体を有するHTLV−IRexタンパク質を暗号化している請 求項4記載の遺伝子、またはHTLV−IRexタンパク質である請求項4記載 のタンパク質、または 野生型Rexタンパク質の約59〜121の間、好ましくは約59、60、64 、65、119、120、または121のアミノ酸位置に突然変異体を有するH TLV−IRexタンパク質を暗号化している請求項4記載の遺伝子、またはH TLV−IRexタンパク質である請求項4記載のタンパク質、またはpcRe xM2、pcRexM7、pcRexM8、pcRexM17、およびpcRe x13Δ15、およびM6、M7およびM13の遺伝子またはタンパク質、また はそれらから誘導された遺伝子またはタンパク質から選ばれた請求項4記載の遺 伝子またはタンパク質、 または機能的なその断片または誘導体。
- (6)HIV−1、HIV−2、SIV、EIAV、ビスナウイルス、またはウ シ免疫不全ウイルスのrev遺伝子の表現型発現をトランス優性に抑制するタン パク質を暗号化している遺伝子またはタンパク質、または機能的なその断片また は誘導体。
- (7)それによってHIVrev遺伝子の表現型発現が抑制される請求項6記載 の遺伝子またはタンパク質、またはそれによってHIVrev遺伝子の表現型発 現が抑制される請求項6記載の遺伝子またはタンパク質、または野生型Revタ ンパク質の約68〜90の間、好ましくは約78〜約86の間、ことに約78〜 約83または84の間のアミノ酸位置に突然変異体を有するHIV−1Revタ ンパク質を暗号化している請求項6記載の遺伝子、またはHIV−1Revタン パク質である請求項6記載のタンパク質、または pM10、pΔ9/14、およびpΔ10/14、およびpM21、pM22、 pM27、pM28、pM29、およびpM32の遺伝子またはタンパク質、ま たはそれらから誘導された遺伝子またはタンパク質から選ばれた請求項6記載の 遺伝子またはタンパク質、または pM10、pM21、およびpM32の遺伝子またはタンパク質、またはそれら から誘導された遺伝子またはタンパク質から選ばれた請求項6記載の遺伝子、ま たは 機能的なその断片または誘導体。
- (8)少なくとも1個のトランス優性な負の突然変異体によってRexタンパク 質の野生型の形から、Rexタンパク質のエフェクター活性を示す寿生型Rex タンパク質のペプチドドメインに修飾を受け、実質上、Rexタンパク質の野生 型の形の核小体局在化活性を有するリプレッサーであるHTLV−IRexタン パク質のトランス優性なりプレッサーを暗号化しているDNAセグメント。
- (9)少なくとも1個のトランス優性な負の突然変異体によってRexタンパク 質の野生型の形から、Rexタンパク質のエフェクター活性を示す野生型Rex タンパク質のペプチドドメインに修飾を受け、実質上、Rexタンパク質の野生 型の形の核小体局在化活性を有するリプレッサーであるHTLV−IRexタン パク質機能のトランス優性なりプレッサー。
- (10)第1ドメインは実質上、野生型HIV−1Revの特異的結合機能を有 し、第2ドメインは野生型HIV−1Revの活性化機能を有せず、第2ドメイ ンは1またはそれ以上の突然変異体によって野生型HTLV−IRevから修飾 されたものである第1ドメインおよび第2ドメインを含んでいるHTLV−IR ev機能のトランス優性なりプレッサー。
- (11)実質上、寿生型Revの特異的結合機能を有する第1ドメインを含んで おり、野生型HIV−1Revの活性化機能を有していないHIV−1Rev機 能のトランス優性なりプレッサー。
- (12)好適な発現系から対応する野生型遺伝子を単離し、この遺伝子を好適な クローニング系へ加えて、所望の突然変異を遺伝子へ導入し、所望の突然変異を 有するクローンから得られた突然変異遺伝子を回収することを含んでなる請求項 1、4および6の何れか1項記載の遺伝子の生産方法。
- (13)好適な発現系および増幅系で請求項1、4および6の何れか1項記載の 遺伝子を発現ならびに増幅し、得られた生産物を回収することを含んでなる請求 項2、4および6の何れか1項記載のタンパク質の生産方法。
- (14)請求項1、4および6の何れか1項記載の遺伝子、または請求項2、4 および6の何れか1項記載のタンパク質、または機能的なその断片または誘導体 を所望の予防または治療効果を達成し得る好適な形で製薬上許容し得る担体また は希釈剤とともに含有している医薬組成物。
- (15)請求項1、4および6の何れか1項記載の遺伝子、または請求項2、4 および6の何れか1項記載のタンパク質、または機能的なその断片または誘導体 を所望の予防または治療効果を達成し得る好適な形でそのような処置を必要とす る対象へ投与することを含んでなるウイルス感染の処置方法。
- (16)HIV−1、HTLV−I、またはHTLV−IIウイルスの何れか1 つを複製し、HTLV−IRex機能トランス優性リプレッサーを産生する該D NAセグメントを発現する能力を有する細胞へ請求項8記載のDNAセグメント を導入することを含んでなるHIV−1、HTLV−I、またはHTLV−II 複製の抑制方法。
- (17)HIV−1で感染させた細胞へHIV−1Rev機能を導入することを 含んでなるHIV−1複製の抑制方法。
- (18)医薬として使用する請求項1、4および6の何れか1項記載の遺伝子、 または請求項2、4および6の何れか1項記載のタンパク質、または機能的なそ の断片または誘導体。
- (19)請求項1、4および6の何れか1項記載の遺伝子、または機能的なその 断片または誘導体を、標的哺乳動物細胞へ機能的な形で送達し得る好適な形態で 含有するベクター。
- (20)トランス優性なドメインを請求項3、5、または7に記載の突然変異体 RexまたはRevタンパク質に似せることができる抑制剤。
- (21)(i)−Rexタンパク質によって認識される調節応答要素、および少 なくとも1個の未使用のスプライス部位を含んでいるmRNAを暗号化している DNAセグメント、−発現されると、核小体からのmRNAの放出を誘発するタ ンパク質生産物を生産することが可能なrex遺伝子を暗号化しているDNAセ グメント、 −rex遺伝子を暗号化しているDNAセグメントおよびmRNAを暗号化して いるDNAによって形質転換され、rex遺伝子のタンパク質生産物の発現能お よびmRNAの発現能を保有する宿主を含んでなる遺伝子系を提供し、 (ii)この遺伝子系の細胞を含有する培養を、Rexタンパク質の特異的抑制 因子であることが疑われる因子が細胞へ侵入するような条件下で該因子と接触さ せ、 (iii)未使用のスプライス部位を含んでいるmRNAの核からの放出に対す るこの因子の効果を測定し、(iv)スプライス部位を使用したmRNAのスプ ライス形態の核からの放出に対する該因子の効果を測定し、それによって未使用 のスプライス部位を含んでいるmRNAの放出を低下し、それと同時にmRNA のスプライス形態が低下しなければ、該因子がHTLV−Irex遺伝子の活性 またはrex遺伝子生産物の活性の特異的な抑制因子であることを示す段階を含 んでなるRexタンパク質の遺伝子活性化機能の特異的抑制因子の同定方法。
- (22)−Rexタンパク質によって認識される調節応答要素を含んでいるmR NA、および少なくとも1個の未使用のスプライス部位を暗号化しているDNA セグメント、−発現されると、核小体からmRNAの放出を誘発するタンパク質 生産物を生産することが可能なRex遺伝子を暗号化しているDNAセグメント 、 −rex遺伝子を暗号化しているDNAセグメント、およびmRNAを暗号化し ているDNAセグメントによって形質転換された細胞であって、rex遺伝子の タンパク質生産物発現能およびmRNA発現能を有する宿主細胞を含有する容器 を含んでなる請求項21記載の同定方法によってRexタンパク質の遺伝子活性 化機能の特異的抑制因子を同定する、因子のスクリーニング試薬用キット。
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35687889A | 1989-05-25 | 1989-05-25 | |
US356,878 | 1989-05-25 | ||
GB898915602A GB8915602D0 (en) | 1989-07-07 | 1989-07-07 | Multivalent repressor of gene function |
GB8915602.0 | 1989-07-07 | ||
GB8924396.8 | 1989-10-30 | ||
GB898924396A GB8924396D0 (en) | 1989-10-30 | 1989-10-30 | Multivalent repressor of gene function |
US44267089A | 1989-11-29 | 1989-11-29 | |
US8924396.8 | 1989-11-29 | ||
US442,670 | 1989-11-29 | ||
US8915602.0 | 1989-11-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP31805597A Division JP3159671B2 (ja) | 1989-05-25 | 1997-11-19 | 遺伝子機能の多価リプレッサー |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04500009A true JPH04500009A (ja) | 1992-01-09 |
JP3126378B2 JP3126378B2 (ja) | 2001-01-22 |
Family
ID=27450368
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP02507933A Expired - Lifetime JP3126378B2 (ja) | 1989-05-25 | 1990-05-23 | 遺伝子機能の多価リプレッサー |
JP31805597A Expired - Lifetime JP3159671B2 (ja) | 1989-05-25 | 1997-11-19 | 遺伝子機能の多価リプレッサー |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP31805597A Expired - Lifetime JP3159671B2 (ja) | 1989-05-25 | 1997-11-19 | 遺伝子機能の多価リプレッサー |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0406557B1 (ja) |
JP (2) | JP3126378B2 (ja) |
KR (1) | KR100215949B1 (ja) |
AT (1) | ATE207122T1 (ja) |
AU (2) | AU648256B2 (ja) |
CA (1) | CA2032158C (ja) |
DE (1) | DE69033829T2 (ja) |
DK (1) | DK0406557T3 (ja) |
ES (1) | ES2166748T3 (ja) |
FI (1) | FI110437B (ja) |
HU (2) | HU217091B (ja) |
IL (1) | IL94482A (ja) |
WO (1) | WO1990014427A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2949310A1 (en) | 2014-05-30 | 2015-12-02 | Shofu Inc. | Dental temporary sealing material comprising an ion sustained-release glass |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2767078B2 (ja) * | 1990-10-17 | 1998-06-18 | アメリカ合衆国 | Hiv―1の分子クローンとその使用法 |
US5534408A (en) * | 1993-09-24 | 1996-07-09 | University Of Massachusetts Medical Center | 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding |
US5650306A (en) * | 1993-06-07 | 1997-07-22 | University Of Michigan | Recombinant nucleic acids for inhibiting HIV gene expression |
AU7263994A (en) * | 1993-08-06 | 1995-02-28 | Kai Juhani Ernst Krohn | Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses |
US5981258A (en) * | 1993-12-13 | 1999-11-09 | Transgene S.A. | Composition of trans-dominant variants of viral proteins for obtaining an antiviral effect |
FR2713651B1 (fr) * | 1993-12-13 | 1996-04-19 | Transgene Sa | Nouvelle composition pour un effet antiviral. |
US6228369B1 (en) | 1993-12-13 | 2001-05-08 | Transgene S.A. | Composition of trans-dominant variants of viral proteins for obtaining an anti-viral effect |
HU226203B1 (en) | 1996-01-26 | 2008-06-30 | Virco B V B A | Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
EP0914423A2 (en) * | 1996-06-06 | 1999-05-12 | Novartis AG | Inhibition of hiv-1 replication by antisense rna expression |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
CA2256484A1 (en) | 1996-06-06 | 1997-12-11 | Novartis Ag | Vectors comprising sar elements |
JP2002536964A (ja) * | 1998-12-22 | 2002-11-05 | サブサイダリー ナンバースリー インコーポレイテッド | ヒト免疫不全ウイルスに対する遺伝子抑制エレメント |
WO2000040606A2 (en) * | 1999-01-06 | 2000-07-13 | The Regents Of The University Of California | Modulation of hiv replication using sam68 |
WO2004064501A2 (en) | 2003-01-23 | 2004-08-05 | Gala Design Inc. | Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935372A (en) * | 1986-05-20 | 1990-06-19 | Dana Farber Cancer Institute | Art nucleotide segments, vectors, cell lines methods of preparation and use |
-
1990
- 1990-05-23 ES ES90109892T patent/ES2166748T3/es not_active Expired - Lifetime
- 1990-05-23 JP JP02507933A patent/JP3126378B2/ja not_active Expired - Lifetime
- 1990-05-23 KR KR1019910700090A patent/KR100215949B1/ko not_active IP Right Cessation
- 1990-05-23 DK DK90109892T patent/DK0406557T3/da active
- 1990-05-23 HU HU904245A patent/HU217091B/hu unknown
- 1990-05-23 IL IL9448290A patent/IL94482A/xx not_active IP Right Cessation
- 1990-05-23 WO PCT/EP1990/000831 patent/WO1990014427A2/en active IP Right Grant
- 1990-05-23 AU AU57388/90A patent/AU648256B2/en not_active Expired
- 1990-05-23 EP EP90109892A patent/EP0406557B1/en not_active Expired - Lifetime
- 1990-05-23 CA CA002032158A patent/CA2032158C/en not_active Expired - Lifetime
- 1990-05-23 DE DE69033829T patent/DE69033829T2/de not_active Expired - Lifetime
- 1990-05-23 AT AT90109892T patent/ATE207122T1/de not_active IP Right Cessation
-
1991
- 1991-01-24 FI FI910371A patent/FI110437B/fi active
-
1994
- 1994-07-20 AU AU67573/94A patent/AU678478B2/en not_active Expired
-
1995
- 1995-06-19 HU HU95P/P00249P patent/HU211530A9/hu unknown
-
1997
- 1997-11-19 JP JP31805597A patent/JP3159671B2/ja not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
JOURNAL OF ACOUIRED IMMUNE DEFICIENCY SYNDROMES=1989 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2949310A1 (en) | 2014-05-30 | 2015-12-02 | Shofu Inc. | Dental temporary sealing material comprising an ion sustained-release glass |
Also Published As
Publication number | Publication date |
---|---|
KR100215949B1 (ko) | 1999-08-16 |
CA2032158A1 (en) | 1990-11-26 |
DE69033829T2 (de) | 2002-04-04 |
AU5738890A (en) | 1990-12-18 |
WO1990014427A2 (en) | 1990-11-29 |
HUT56135A (en) | 1991-07-29 |
AU678478B2 (en) | 1997-05-29 |
ATE207122T1 (de) | 2001-11-15 |
JP3159671B2 (ja) | 2001-04-23 |
EP0406557B1 (en) | 2001-10-17 |
AU648256B2 (en) | 1994-04-21 |
KR920701440A (ko) | 1992-08-11 |
CA2032158C (en) | 2009-09-15 |
DK0406557T3 (da) | 2002-02-11 |
JP3126378B2 (ja) | 2001-01-22 |
IL94482A0 (en) | 1991-03-10 |
JPH10165188A (ja) | 1998-06-23 |
HU217091B (hu) | 1999-11-29 |
HU904245D0 (en) | 1991-06-28 |
EP0406557A3 (en) | 1991-05-02 |
WO1990014427A3 (en) | 1991-01-10 |
FI910371A0 (fi) | 1991-01-24 |
EP0406557A2 (en) | 1991-01-09 |
DE69033829D1 (de) | 2001-11-22 |
IL94482A (en) | 2003-09-17 |
FI110437B (fi) | 2003-01-31 |
AU6757394A (en) | 1994-11-17 |
HU211530A9 (en) | 1995-11-28 |
ES2166748T3 (es) | 2002-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6107062A (en) | Antisense viruses and antisense-ribozyme viruses | |
US5597895A (en) | Transdominant tat mutants and uses thereof | |
Ruben et al. | Structural and functional characterization of human immunodeficiency virus tat protein | |
JP4234999B2 (ja) | 治療標的としてのhiv−1vifタンパク質の多量体形成 | |
CA2132208C (en) | Method of eliminating inhibitory/instability regions of mrna | |
Ballaun et al. | Functional analysis of human T-cell leukemia virus type I rex-response element: direct RNA binding of Rex protein correlates with in vivo activity | |
US8197821B2 (en) | Human immunodeficiency virus integrase—Transportin—SR protein—protein interactions | |
JPH04500009A (ja) | 遺伝子機能の多価リプレッサー | |
US5994108A (en) | Mutant TAR virus and transdominant tat mutants as pharmacological agents | |
US5688511A (en) | Cellular protein TDP-43 and regulation of HIV-1 gene expression | |
AU668441B2 (en) | New transdominant TAT variants of the human immunodeficiency virus | |
US8685652B2 (en) | Targets and compounds for therapeutic intervention of HIV infection | |
SADAIE et al. | Conservative mutations in the putative metal-binding region of human immunodeficiency virus tat disrupt virus replication | |
US5871958A (en) | Mutant rev genes encoding transdominant repressors of HIV replication | |
US5843724A (en) | Chimeric nucleic acids and proteins for inhibiting HIV-1 expression | |
US6251675B1 (en) | Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication | |
AU720284B2 (en) | Multivalent repressor of gene function | |
WO1994002606A1 (en) | Inhibition of retroviral expression by interferon-induced cellular genes and proteins | |
US5922856A (en) | Human protein critical for HIV replication | |
KR100231318B1 (ko) | 종양괴사인자 알파 수용체의 c-말단 부분을 갖는 레트로바이러스 벡터 및 이를 이용한 hiv-1 증식 억제 방법 | |
IE83555B1 (en) | Multivalent repressor of gene function | |
Orsini et al. | Purification and Functional Characterization of Wild-Type and Mutant HIV-1 and HIV-2 Tat Proteins Expressed inEscherichia coli | |
Bakker | The regulation of RNA processing by the Rex protein of human T cell leukemia virus type II | |
Malim et al. | The HIV-1 REV Trans-Activator is a Sequence Specific RNA Binding Protein | |
WO1997006257A9 (en) | Cellular co-factor for hiv rev and htlv rex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071102 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 10 |